Doxycycline
Efracea and Oracea are different trade names for the same medicine.
Table of Contents of the Leaflet:
Efracea is a medicine used in adults to reduce the redness and number of pimples caused by a condition called rosacea.
Do not give Efracea to infants or children under 12 years old, as it may cause permanent tooth discolouration or affect tooth development.
Efracea must not be used to treat infections caused by bacteria.
Before taking Efracea, discuss this with your doctor. Tell your doctor if you have:
Efracea may cause permanent tooth discolouration.
Tell your doctor or pharmacist if, during treatment, you:
Take the medicine as directed by your doctor. Taking a higher dose of Efracea than recommended by your doctor may increase the risk of bacteria in the gut becoming resistant to Efracea.
Tell your doctor about all the medicines you are taking now or have taken recently, as well as any medicines you plan to take.
Efracea and some other medicines may not work properly if taken together.
Tell your doctor about the medicines you are taking or plan to take at the same time as Efracea.
Always take the Efracea capsule with a sufficient amount of water, as this reduces the risk of irritation or ulceration of the throat and oesophagus.
Do not take milk or dairy products at the same time as Efracea, as they contain calcium, which may reduce the effectiveness of Efracea. Wait for 2 to 3 hours after taking your daily dose of Efracea before consuming dairy products.
Do not take Efracea during pregnancy, as it may cause permanent tooth discolouration in the child.
Do not take Efracea for a long time during breast-feeding, as it may cause tooth discolouration and affect bone development in the breast-fed child.
If you are pregnant, think you may be pregnant, or plan to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Efracea has no or negligible influence on the ability to drive and use machines.
per capsule.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Efracea.
The ink used to mark the capsules contains Allura Red AC (E 129), which may cause allergic reactions.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
The recommended dose is one Efracea capsule every day in the morning on an empty stomach or, if necessary, 1 hour before or 2 hours after a meal. Swallow it whole, without chewing.
Take Efracea with a full glass of water, sitting or standing upright, to reduce the risk of throat irritation.
If you take more Efracea than you should, there is a risk of liver, kidney, or pancreas damage.
If you have taken more Efracea capsules than you should, contact your doctor immediately.
Do not take a double dose to make up for a forgotten capsule.
Continue taking Efracea for as long as your doctor tells you.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Efracea can cause side effects, although not everybody gets them.
If you experience any of the following side effects, contact your doctor immediately:
Common Side Effects
The following side effects are common (affecting 1 to 10 in every 100 patients) when taking Efracea:
Uncommon Side Effects (frequency cannot be estimated from the available data)
The following side effects may occur when taking Efracea:
Rare Side Effects
The following side effects are rare (affecting 1 to 10 in every 10,000 patients) when taking tetracycline-class medicines like Efracea:
Very Rare Side Effects
The following side effects are very rare (affecting less than 1 in every 10,000 patients) when taking tetracycline-class medicines like Efracea:
Side Effects with Unknown Frequency (frequency cannot be estimated from the available data)
Side effects that may occur when taking medicines in the same class as Efracea (tetracyclines):
* If you notice any of the following side effects, contact your doctor immediately: swelling of the face, lips, tongue, or throat, difficulty breathing, tingling or itching of the skin and eyes, or rapid heartbeat (palpitations) and tendency to faint. These may be signs of a severe allergic reaction (hypersensitivity).
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. You can also report side effects directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocides of the Office for Registration of Medicinal Products, Medical Devices, and Biocides, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Store in the original packaging to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substance is doxycycline. Each capsule contains 40 mg of doxycycline (as doxycycline monohydrate).
The other ingredients are: hypromellose 2910, methacrylic acid - ethyl acrylate copolymer (1:1), triethyl citrate, talc, Opadry Beige, YS-1-17274-A consisting of hypromellose 3cP, hypromellose 6cP, titanium dioxide, macrogol 400, iron oxide yellow, iron oxide red, polysorbate 80; sucrose, pellets (maize starch, sucrose).
The capsule shell (Hard Gelatin Capsule no 2, beige Opaque) consists of: iron oxide black, iron oxide red, iron oxide yellow, titanium dioxide, gelatin.
The ink consists of: shellac, propylene glycol, iron oxide black, indigo carmine, Allura Red AC (E 129), Brilliant Blue FCF, aluminium lake, Quinoline Yellow.
Modified release hard capsules. Beige capsules, size 2, marked "GLD 40".
Efracea is available in packs of 28 or 56 capsules.
For more detailed information, contact the marketing authorisation holder or the parallel importer.
GALDERMA INTERNATIONAL
Tour Europlaza
20 avenue André Prothin - La Défense 4
92 927 Paris La Défense Cedex
France
Patheon France
40 boulevard de Champaret
38300 Bourgoin-Jallieu, France
Laboratoires GALDERMA
Zone Industrielle Montdésir
74540 Alby-sur-Chéran, France
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing Authorisation Number in Greece, the Country of Export:109605/19-09-2019
ORACEA 40 mg modified release hard capsules - DK, EL, ES, FI, IS, SE, NO
ORAYCEA 40 mg modified release hard capsules - AT, DE
EFRACEA 40 mg modified release hard capsules - BE, FR, IE, IT, LU, NL, PL, PT, UK
[Information about the Trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.